Strategies to improve drug development for sepsis

@article{Fink2014StrategiesTI,
  title={Strategies to improve drug development for sepsis},
  author={Mitchell P. Fink and H. Shaw Warren},
  journal={Nature Reviews Drug Discovery},
  year={2014},
  volume={13},
  pages={741-758}
}
Sepsis, a common and potentially fatal systemic illness, is triggered by microbial infection and often leads to impaired function of the lungs, kidneys or other vital organs. Since the early 1980s, a large number of therapeutic agents for the treatment of sepsis have been evaluated in randomized controlled clinical trials. With few exceptions, the results from these trials have been disappointing, and no specific therapeutic agent is currently approved for the treatment of sepsis. To improve… 
Could Biomarkers Direct Therapy for the Septic Patient?
TLDR
This review supports the concept that identification of the right biomarkers that can direct therapy and provide timely feedback on its effectiveness will enable critical care physicians to decrease mortality of patients with sepsis and improve the quality of life of survivors.
Sepsis: a roadmap for future research.
Immunotherapy of Sepsis: Blind Alley or Call for Personalized Assessment?
TLDR
A careful daily review of the patient’s immune status needs to be introduced into routine clinical practice giving the opportunity for effective and tailored use of immunomodulatory therapy.
Sepsis: pathophysiology and clinical management
TLDR
Outcomes in sepsis have greatly improved overall, probably because of an enhanced focus on early diagnosis and fluid resuscitation, the rapid delivery of effective antibiotics, and other improvements in supportive care for critically ill patients.
Recent developments in severe sepsis research: from bench to bedside and back.
TLDR
Some recent developments in understanding of the associated systemic inflammatory response that help deciphering pathophysiology are highlighted and some of the consequences of sepsis are discussed.
Recent advances in nanomedicine for sepsis treatment.
TLDR
Recently, several nanoparticle (NP) systems have shown excellent protective effects against sepsis in preclinical models, suggesting a potential utility in the management of sepsi and septic shock, and a review discusses the recent developments in NP-based approaches.
Neutrophil dysregulation during sepsis: an overview and update
TLDR
The potential of neutrophils as a target to specifically diagnose and/or predict the outcome of sepsis is discussed, and an overview of the associated mediators and signal pathways involved are provided.
Recent advances in neutrophil chemotaxis abnormalities during sepsis.
  • Yu-ying ZhouB. Sun
  • Medicine, Biology
    Chinese journal of traumatology = Zhonghua chuang shang za zhi
  • 2022
Septic Shock
TLDR
For more than 20 years, sepsis has been defined as symptoms associated with the response to microorganism infection, which was more specifically called systemic inflammatory response syndrome (SIRS), but no specific drug has survived in clinical use even though many candidate drugs have been successfully investigated in preclinical setting.
...
...

References

SHOWING 1-10 OF 223 REFERENCES
Animal models of sepsis
  • M. Fink
  • Biology, Medicine
    Virulence
  • 2014
TLDR
Preclinical studies of new therapeutic agents for sepsis must be viewed with a degree of skepticism because many species, including mice and baboons, are remarkably resistant to the toxic effects of bacterial lipopolysaccharide, whereas humans are exquisitely sensitive.
ANIMAL MODELS OF SEPSIS AND SHOCK: A REVIEW AND LESSONS LEARNED
TLDR
The goal of this review article is to review the advantages and disadvantages of commonly used sepsis and shock models in light of lessons learned from these clinical trials.
Cytokines in Sepsis: Potent Immunoregulators and Potential Therapeutic Targets—An Updated View
TLDR
This review addresses the current knowledge of the actions of pro- and anti-inflammatory cytokines in sepsis pathophysiology as well as how these cytokines and other important immunomodulating agents may be therapeutically targeted to improve the clinical outcome of sepsi.
NEUTRALIZATION OF TUMOR NECROSIS FACTOR IN PRECLINICAL MODELS OF SEPSIS
TLDR
It is concluded that the beneficial effects of T NF in systemic inflammation occur at the cost of impaired antimicrobial defenses, and that a better understanding of the consequences of neutralization of TNFα in vivo could aid in better defining optimal patient populations for therapeutic intervention.
Antitumor Necrosis Factor Therapy Is Associated With Improved Survival in Clinical Sepsis Trials: A Meta-Analysis*
TLDR
Antitumor necrosis factor agents produced a modest but significant decrease in the risk of dying with sepsis, and prior individual trials failed to demonstrate benefit, likely because they were underpowered.
Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study.
TLDR
The circulating cytokine response to pneumonia is heterogeneous and continues for more than a week after presentation, with considerable overlap between those who do and do not develop severe sepsis.
A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections: A Randomized Clinical Trial.
TLDR
AB103 is a safe, promising new agent for modulation of inflammation after NSTI and is warranted to establish efficacy, according to clinicaltrials.gov.
A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group.
TLDR
In this study, E5 did not reduce mortality in nonshock patients with Gram-negative sepsis whether or not those patients also had organ failure, but E5did result in greater resolution of organ failure in patients with gram-negative Sepsis and E5 resulted in the prevention of adult respiratory distress syndrome and central nervous system organ failure.
Sepsis‐induced human lymphocyte apoptosis and cytokine production in “humanized” mice
TLDR
Results show that the humanized mouse model recapitulates many of the classic findings in patients with sepsis, and represents an advanced, clinically relevant model for mechanistic studies of sepsi and testing of novel therapies.
...
...